A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism

A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism

The primary objective of this study is to collect safety and effectiveness data for the Technolas Teneo 317 Model 2 excimer laser for LASIK correction in participants with myopia and myopic astigmatism.

Study Overview

• Status: Completed
• Conditions: Myopia; Myopic Astigmatism
• Intervention / Treatment: Device: Technolas® TENEO 317 Model 2

Detailed Description

Technolas TENEO 317 Model 2 excimer laser is a scanning excimer laser that operates at 193 nm ultraviolet wavelength to photoablate corneal tissue in order to achieve a refractive change. It is planned to enroll and treat up to 334 participant eyes, with an expectation that 300 study eyes will complete post-surgical follow-up for 6 months or until the point of achieved refractive stability. When a cohort of at least 300 eyes has achieved refractive stability at 6 months post-surgery, all other treated eyes that have not reached the 6-month examination may be discontinued at the Sponsor's request. Or, if 300 eyes achieve refractive stability at 9 months post-surgery, all other treated eyes that have not reached the 9-month examination may be discontinued

• Study Type: Interventional
• Enrollment (Actual): 336
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Newport Beach, California, United States, 92663
      • Bausch Site 101
  • Minnesota
    • Blaine, Minnesota, United States, 55434
      • Bausch Site 110
    • Bloomington, Minnesota, United States, 55420
      • Bausch Site 107
  • Nebraska
    • Omaha, Nebraska, United States, 68105
      • Bausch Site 108
  • New Hampshire
    • Portsmouth, New Hampshire, United States, 03801
      • Bausch Site 106
  • New York
    • Amherst, New York, United States, 14228
      • Bausch Site 102
  • North Carolina
    • Greensboro, North Carolina, United States, 27401
      • Bausch Site 104
  • South Carolina
    • Mount Pleasant, South Carolina, United States, 29464
      • Bausch Site 103
  • South Dakota
    • Sioux Falls, South Dakota, United States, 57108
      • Bausch Site 109
  • Texas
    • Cedar Park, Texas, United States, 78613
      • Bausch Site 105

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Are 22 years of age or older.
• Have read, understood, and signed an informed consent form (ICF).
• Have demonstrated stable refraction (for example, a change of ≤0.5 D in sphere and cylinder) for a minimum of 12 months prior to surgery, verified by consecutive refractions and/or medical records or prescription history.
• Have myopic refractive error with or without astigmatism; sphere between -1.0 D and -10.00 D, cylinder between 0.0 D and -3.0 D; with a manifest refraction spherical equivalent (MRSE) between -1.0 D and -11.50 D.
• Have uncorrected distance visual acuity (UDVA) of 20/40 or worse.
• Have manifest distance best spectacle corrected visual acuity (BSCVA) of 20/25 (logarithm of the minimum angle of resolution [logMAR] 0.1) or better in an operative eye.
• Have equal to or less than 0.50 D spherical equivalent (SE) difference between cycloplegic and manifest refractions at Visit 1 (pre-operative).
• Have normal corneal topography as determined by the Investigator.
• Have discontinued use of contact lenses for at least 2 weeks (for hard or toric lenses) or 3 days (for soft contact lenses) prior to the pre-operative examination, and through the day of surgery.
• All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as determined by MRSE, on 2 consecutive examinations at least 1 week apart, in an eye to be treated and the axis of cylinder should not differ by more than 15 degrees from the baseline cycloplegic refraction.
• Have the ability to lie flat without difficulty.
• Are willing and able to comply with the schedule for all post-surgery follow-up visits.

Exclusion Criteria:

• Participants for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in treatment depth less than 250 microns from corneal endothelium.
• Eyes for which the baseline manifest subjective refraction exhibits a difference greater than 0.50 D in sphere power, or a difference greater than 0.50 D in cylinder power, or a difference in cylinder axis of more than 15 degrees compared to the baseline cycloplegic subjective refraction. For manifest cylinder of less than 0.50 D, the difference in cylinder axis will not be taken into consideration.
• Participants for whom the pre-operative assessment of the cornea indicates that one or both eyes are not suitable candidates for treatment based upon the Investigator's medical judgment.
• Have evidence of retinal vascular disease.
• Have a history of or have active corneal disease or infection (for example, recurrent corneal erosion syndrome, herpes simplex, or herpes zoster keratitis) in either eye.
• Have a known sensitivity to any study medication.
• Have central corneal scars affecting visual acuity or unstable keratometry with irregular mires in an eye considered for eligibility.
• Have keratoconus, subclinical or forme fruste keratoconus, corneal dystrophy, or other corneal irregularity (for example, irregular astigmatism).
• Have visually significant or progressive cataract in an eye considered for eligibility.
• Had previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the participant.
• Use chronic medications by any administration route that may increase risk to the participant or may confound the outcome of the study, including those known to affect wound healing (for example, corticosteroids, antimetabolites).
• Are known to have acute or chronic disease or illness (for example, dry eye, cataract, glaucoma, immuno-compromised, rheumatoid arthritis, clinically significant atopic disease, acne rosacea) that would increase operative risk or may confound the results of the study.
• Are taking medications contraindicated for LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).
• Are known to be pregnant, lactating, or who plan to become pregnant during the course of the study.
• Have known sensitivity to medications used for standard LASIK.
• Have the presence of systemic disease likely to affect wound healing, for example, autoimmune disease, systemic connective tissue disease, diabetes, or severe atopic disease.
• Are participating in any other ophthalmic clinical trial within 30 days of screening or during this clinical trial.
• Have an ocular muscle disorder including a strabismus or nystagmus, or other disorder affecting fixation.
• Have a history of or evidence of glaucoma or are a glaucoma suspect.
• Have eyes with mesopic pupil size >7.0 millimeters (mm).
• Have a Schirmer's pre-operative test without anesthesia <4 mm/5 minutes.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Technolas TENEO 317 Model 2; One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0.	Device: Technolas® TENEO 317 Model 2; LASIK eye surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Eyes that Achieve MRSE Predictability within ±0.50 Diopter (D) and ±1.00 D	Predictability is defined as the difference between the attempted and achieved manifest refraction spherical equivalent (MRSE) at the time of refractive stability.	Month 3 up to Month 9
Percentage of Eyes Targeted for Emmetropia that Achieve Uncorrected Distance Visual Acuity (UDVA) of 20/40 or Better	Percentage of eyes targeted for emmetropia that achieve UDVA of 20/40 or better at the point at which refractive stability is reached.	Month 3 up to Month 9

Collaborators and Investigators

• Sponsor: Bausch & Lomb Incorporated
• Investigators: Study Director: Anya Loncaric, Bausch & Lomb Incorporated

Study record dates

Study Major Dates

• Study Start (Actual): July 25, 2019
• Primary Completion (Actual): August 6, 2021
• Study Completion (Actual): August 6, 2021

Study Registration Dates

• First Submitted: September 30, 2019
• First Submitted That Met QC Criteria: September 30, 2019
• First Posted (Actual): October 1, 2019

Study Record Updates

• Last Update Posted (Actual): May 11, 2022
• Last Update Submitted That Met QC Criteria: May 4, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: LASIK; Excimer Laser
• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors; Astigmatism; Myopia
• Other Study ID Numbers: 884

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes